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understanding the different types of treatment can help individuals hinder their daily conflicts 
with asthma.  
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Abstract: Medical research has created multitudes of medications to help control the symptoms 
of asthma. Asthmas effects the respiratory system in different ways, creating unique challenges 
to researchers and doctors alike to create or a manage the symptoms of asthma. Identifying the 
common treatment methods and understanding their effect on the human physiology can aid in 
treating patients. The goal of this review is to identify the common medications used to treat 
asthma, how these medications work on the human’s physiology, as well as bring to light a new 
upcoming medication with greater asthma control. As asthma research continues, the need for 
more advanced treatment options can decrease the symptoms of asthma.   
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Introduction: 
Asthma is classified as a chronic inflammatory lung disorder associated with airway 
obstruction and hyper-responsiveness (1). Asthma is the most common chronic illness in 
children and affects children worldwide, yet also affects people of all ages (2). Asthma can 
impact the quality of life on more than just the individual, but the family as a whole. It is 
common for families to have issues with missing school, work, sleep, and daily activities (3). 
The diversity of physiological symptoms asthma obstructs on the body implicates many different 
modes of treatment used for its management.  
What is asthma: 
As mentioned above, asthma is often characterized by airway inflammation and airway 
narrowing, resulting in wheezing, dyspnea, and coughing (4). These symptoms are often 
reoccurring while also determining the severity and treatment options for asthma (26). This 
chronic inflammation is associated with proinflammatory cells like mast cells, lymphocytes, 
eosinophils, and detached airway epithelial cells. Long term inflammation will damage airways 
and initiate airway remodeling resulting in fibrosis under the basement membrane, hypertrophy 
of smooth muscle, and submucosal gland hyperplasia. Ultimately causing irreversible airflow 
limitation and hyperresponsiveness of the airway (4). These symptoms cause episodes of 
wheezing, breathlessness, and chest tightness that are associated with airflow obstruction that 
spontaneously reverses on its own or with treatment (26). These symptoms often appear from 
stimuli such as cold air or exercise (29). Traditionally, asthma has been categorized in two 
forms: allergic, and non-allergic (intrinsic) as illustrated in fig. 1. (29). The two differ in many 
ways but are more similar than dissimilar. Both elicit different responses from the immune 
system yet have similar symptoms. Allergic asthma is expressed in both adults and children, 
which also coincides with allergies sensitizations with the presence of IgE, and proteins 
associated with animal dander, spores, pollen, peanuts, or dust mites (29). The progression from 
allergic sensitization 
accompanies eczema is 
followed by allergic rhinitis 
and then commonly progresses 
to asthma.  Non-allergic often 
doesn’t develop until later in 
life, does not have IgE 
reactivity in serum, nor 
adaptive immune system 
involvement from type 2 
helper T-cells (29). The 
division between just allergic and 
non-allergic is an over 
simplification, as research uncovers different phenotypes that each have a distinctive 
pathophysiology and defined as an endotype. These endotypes can be different in many factors 
such as: risk, age of onset, medicinal responses and prognosis, and genetic susceptibility (29, 5).   
 
 
Figure 1. Example downstream effects leading to the 
pathophysiology of asthma caused by allergens and non-
allergens.  
Causes of Asthma:  
 
           Asthma is a multifactorial disease associated with many different variables that contribute 
to its severity or phenotype (5). Although there is not a definitive cause that leads to the 
inflammatory process, research has shown that genetics has a large interplay in its development 
(26). During the course of development for children, environmental exposures also have a large 
role due their developing immune system (26). A number of studies have shown the prevalence of 
asthma increases in adults and children due to smoking or exposure to tobacco smoke (27). Air 
pollutants such as ozone and particulate matter show decrease in lung function, exacerbation 
triggering, and increasing rates of hospital stays may be linked to initial asthma development (27). 
More research is uncovering the causation of obesity and diet’s role in the development of asthma. 
Increasing evidence is relating body mass to the prevalence and incidence of asthma in both 
children and adults. These same studies and demonstrating that weight loss tends to improve lung 
function and relieve some symptoms of asthma (27). Studies are also conducted to determine what 
foods in the diet may lead to asthma yet lack clear evidence or associations (27). 
Exposure to microbial substances or infections, especially early in life, may lead to increased risk 
of developing asthma (5, 27). 
 
Diagnosing Asthma:  
 
Diagnosing asthma is an arbitrary process that does not have a clear measurement test to 
determine asthma (16). Asthma in children is often presented as being wheezy, although wheezy 
may mean an obstruction has occurred, but asthma may be contributed to other variables as well 
(16). Clinicians are held responsible for determining if these episodic symptoms are contributed 
to asthma (26). Spirometry is often used to asses airflow obstruction and to measure peak flow. 
Other physical examinations look to find indications of asthma from upper respiratory tract, 
abnormal chest sounds form breathing, as well as skin abnormalities (26). Extensive work up for 
determining that asthma is the underlying cause of symptoms is important, due to other health 
issues resulting in the physical symptoms instead of asthma (26). Underlying issues such as 
vocal cord dysfunction, obstructive sleep apnea, and allergic bronchopulmonary aspergillosis 
may coexist or mimic the symptoms of asthma (26). Once asthma is determined as the cause of 
symptoms, the clinicians main aim is to maintain the control over the asthma symptoms; yet each 
patient may respond differently to such treatments (26,16). Differences in asthma severity also 
complicates diagnosis, as well as different responses in sensitivity to diagnostic tests such as 
response to bronchodilators or corticosteroids (28). Recent advancements have allowed more 
accurate diagnosis in regard to measuring exhaled nitric oxide and sputum analysis to identify 
airway inflammation (28). Other tests such as x-rays, pulmonary function studies for COPD, 
lung restrictive defect tests, and inspiratory flow tests may be conducted to exclude other 
underlying issues (26).  
Methods: 
This review was written with the help of Academic Search Premier, and EBSCOHost for 
aiding in relevant articles. Hilton M. Briggs library also aided in use of interlibrary loans of 
material previously inaccessible. Keywords searched in seeking articles included: asthma, 
asthma treatments, diagnosing asthma, asthma causations, monoclonal antibodies, 
corticosteroids, leukotriene modifiers, and bronchodilators.    
 
Asthma Treatments: 
  
Due to asthma’s multiple routes of inflammation within the respiratory tract has required 
the development of multiple classes of treatment. Many of these treatments have been proven to 
be more efficient at treating certain phenotypes of asthma over others, where as other classes are 
shown to prevent symptoms for different amounts of time. Each class of drug discussed has 
different modes of action against asthmas inflammatory response. The classes of drugs discussed 
in this review include monoclonal antibodies, corticosteroids, leukotriene modifiers, and 
bronchodilators.  
 
Monoclonal Antibody:  
 
Omalizumab is a monoclonal antibody that binds and inactivates IgE by binding to the 
FcεRI receptor on mast cells or basophils. As seen on fig. 1, binding of omalizumab to these 
receptors results in a reduced inflammatory response by inactivating effector cells release of 
leukotrienes and interleukins. Omalizumab was originally developed for patients six years or 
older dealing with severe persistent allergic asthma (9, 36). Omalizumab is also found effective 
for patients with multiple exacerbations, despite daily uses of corticosteroids or long activating 
beta2-agonist.   
 A study conducted by 
Hutyrova on the effects of 
omalizumab with 310 patients 
enrolled in a twelve-month study 
showed a significant reduction in 
the need of corticosteroids for 
asthma exacerbations compared to 
the start of treatment. The 
prescribed dosage of 
corticosteroids was reduced by an 
average of 15% compared to their 
Figure 1. Omalizumab’s mode of action taken during an 
allergen response (36).  
baseline averages. Prescribed omalizumab results in an improvement in asthma control, 
reduction in asthma exacerbations, reduced asthma hospitalizations, and reduced dosage of 
corticosteroids.   
Omalizumab also had effects on patients with allergic rhinitis, atopic dermatitis, and food 
allergies. In the case of allergic rhinitis, symptoms disappeared in 18.7% and improved in 63.5% 
of individuals. Individuals with atopic dermatitis experienced resolved symptoms, 5.8% of 
individuals, and improvement in 46.3% of individuals. Individuals experiencing food allergens 
gained complete remission in 39.7% and improvement in 27.6% of the studies participants. 
Indicating omalizumab’s capability of reducing overall inflammation responses due to allergies 
and not just asthmas.  
 An observational study implemented in Canada revealed similar outcomes to that of 
Hutyrova. Omalizumab is part of the Canadian asthma protocol, this study aimed to understand 
the efficacy and safety in its treatment in patients with moderate to severe asthma, as well as the 
corticosteroid sparing effect of treatment.  
 Documented patients from the study were prescribed oral corticosteroids (OCS) for daily 
use or as needed. The majority of these individuals used OCS periodically for exacerbations, 
while 25% had used them for daily management for their asthma. The mean total OCS dose pre-
study was calculated as 2301.5 mg. Completion of the study revealed significant reduction in the 
prescribed OCS dosage was reduced to a mean total of 1130.0 mg post study. This dosage 
equated to a 50% reduction in annual OCS dosage as well as enabling 70.8% of patients to either 
stop or reduce dosage by 40% or more. Asthma control was also found improved with the 
treatment of omalizumab.  
Reduced needs of corticosteroids have many potential benefits to the individuals relying 
on them to reduce their daily asthma symptoms. Individuals were able to reduce their 
corticosteroid usage as well as decrease in their potential side effects such as: increased infection 
risk, hypertension, cataracts, bone density, and diabetes.  Canadian study indicates individuals 
were seen to have an increased life benefit that enabled better self-control of their asthma with 
omalizumab, as well as aiding in potential health risks associated with corticosteroid usage.  
Side effects found tend to be relatively minor with the prescribing of omalizumab. The 
most common side effects being headache, nausea, fatigue, weight gain, and paresthesia. Only 
3.5% of patients in Hutyrova’s study discontinued therapy, with no serious side effects (9). In 
comparison with the benefits of omalizumab, the benefits greatly out-weight the potential side 
effects.  
Corticosteroids:    
Inhaled corticosteroids are the first line treatment options for persistent asthma. 
Corticosteroids work by suppressing the inflammation in the airways of the lungs by binding to 
the glucocorticoid receptor, repressing inflammatory genes, and reverses histone acetylation. 
Glucocorticoids have also been found to regulate 
genes associated with the epithelial barrier and 
airway remodeling (8, 34). These processes are 
displayed in fig. 3. An action taken by some 
corticosteroids is to upregulate the transcription 
of anti-inflammatory genes such as lipocortin, 
protease inhibitor, and plasmin activator 
inhibitors (34). Many corticosteroids work to 
Figure 3. Illustrates the mode of action corticosteroids 
use on cells of the airway during asthma inflammation.  
suppress activator protein 1 (AP1) and nuclear factor-kB (NF-kB) that initiate transcription of 
inflammatory genes. NF-kB regulates genes for many cytokines seen in asthma responses such 
as interleukins; chemokines; tumor necrosis factor-α (TNF-α); nitric oxide synthase; and 
adhesion molecules. Another action is an upregulated expression of NF-kB inhibitors known as 
nuclear factor protein (IkBα) (34).   
Corticosteroids are often administered by two main types, inhaled corticosteroids (ICS) 
and long-acting B-agonist (LABA) in combination. They are administered via dry powdered 
inhalers (DPI) or pressurized metered-dose inhalers (pMDIs). The patient preferred choice is 
inhaled corticosteroid and long acting B-agonist combination (11). Both methods of drug 
delivery have limitations, such as particle size, flow rate, and loss of dose through exhalation.  
Today, there are several different types of devices and delivery methods that are currently usable 
for corticosteroid administration, making it hard to determine which method is appropriate for 
different asthma responses.  
 Corticosteroid use was found to have a reduction in daily exacerbations, as well as a 
reduced need for Montelukast and bronchodilator use (33). This study by Guilbert followed a 
large group of toddlers through two years of fluticasone used twice daily. Exacerbations were 
found to be significantly reduced in toddlers using fluticasone during the study. Guilbert’s study 
continued follow ups on these toddlers a year post treatment of fluticasone and discovered 
exacerbation and symptoms resurfaced after stopping fluticasone use. Guilbert was able to 
determine that corticosteroid therapy is not a disease modifying treatment for asthma symptoms 
(33).  
A Japanese study conducted by Masato and Kyuya aimed to determine which device 
should be used for patients with specific asthma characteristics such as drug benefits, side 
effects, and patient preferences. The study utilized two different delivery methods, DPIs and 
pMDIs, that delivered the same amount of salmeterol/fluticasone preparation combination (SFC). 
The drug of choice known as (Adoair) is available in both types, Adoair DPI (Diskus) and 
Adoair pMDI (Aerosol) and was administered in the same dosage.  
It was found that patients preferred to use pMDI 44%, while 29.4% preferred to use the 
DPI. This was most likely correlated due to patients referring hoarseness, throat irritation, and 
throat discomfort as a major side effect of DPI. Masato’s study indicates aerosol as the preferred 
method amongst patients, as well as the method most likely to be used. Masato’s study illustrated 
that prescribing pMDI may be preferred but may be limited to patients with different severities 
of asthma (11).  
Leukotriene modifiers:       
Leukotriene modifiers are recommended for patients with moderate to severe persistent 
asthma. They work by reducing bronchoconstriction and have anti-inflammatory effects (8). 
Leukotriene modifiers are grouped into two categories: cysteinyl LT1 receptor antagonists and 5-
lipooxygenase pathway inhibitors. These classes of drugs target cysteinyl leukotrienes (cysLTs) 
as well as other leukotrienes (LTA4, LTB4, LTC4, LTD4 and LTE4) which are created through 
5-lipoxygenase pathway and expressed during many types of activated inflammatory cells during 
allergic airway inflammation. Each leukotriene may be expressed more some individuals than 
others which may induce different pathophysiological responses patient to patient (12).  
 The 5-lipooxygenase pathways results in the 
creation of the LT classes: LTA4, LTB4, LTC4, 
LTD4, and LTE4. The pathway is normally limited to 
the myeloid cells: neutrophils, eosinophils, 
monocytes/macrophages, mast cells and B 
lymphocytes. LTs LTC4, LTD4, and LTE4 are 
generally produced in alveolar macrophages, 
eosinophil epithelial cells and vascular endothelial 
cells in the airways and the lungs. The creation of 
these proteins act upon the LT receptors present on 
cell membranes. As seen on fig. 4 below, LTB4 
activates LT B-receptor (BLT), CysLT activates 
CysLT receptors 1 and 2 which are G-protein coupled proteins expressed in monocytes, 
macrophages, eosinophils, basophils, mast cells T cells, smooth muscle cells and vascular 
endothelial cells. The activated CysLTs are the most potent airway constrictor muscles known. 
CysLT also acts with granulocyte macrophage colony stimulating factor, known as Interleukin -
5, to cause growth of progenitor cells. CysLTs also illicit the proliferation of lung fibroblasts 
leading to progressive loss of lung function in chronic asthma. CysLT receptor antagonism also 
affects the anti-remodeling effects in the airways, and inhibitory effects on airway structural cells 
that remodeling airway inflammation in asthma patients.  LTB4 is the strong chemotactic 
inflammatory seen in asthma exacerbations in patients with severe asthma (13). 
Figure 4. Illustrates the mode of action of 
Montelukast, Zafirlukast, Pranlukast, and 
Zileuton (13).  
LT modifiers used in clinical practice for asthma treatment are seen on table 1. This table 
includes two different groups including leukotriene receptor antagonists (LTRA): pranlukast, 
zafirlukast, and Montelukast and a second group being a LT biosynthesis inhibitor zileuton. The 
modes of action of these drugs are shown on fig. 4. Montelukast, pranlukast, and zafirlukast 
work by inhibiting the binding of cysteinyl leukotrienes, LTC4, LTD4, and LTE4 from binding 
to the CysLT1 receptor of many airway effector cells. Zileuton, a LT biosynthesis inhibitor, 
works by blocking the 5-lipooxygenase pathway, as illustrated in fig. 4. Zileuton’s blocking 
mechanism prevents the production of LTA4, LTB4, and LTC4 that initially bind to effecter cell 
receptors and produce the physiological symptoms presented in asthma.  
Montelukast studies reveal exacerbations reduced to half 50% along with a reduction of 24% in 
B2 agonist use. Montelukast studies revealed that children proved to adhere better with the oral 
does than inhaled corticosteroid. Parents found Montelukast favorable in terms of ease of use due 
easy administration and taste in the use of children (15).  
Pranlukast has a mixture of results from different studies (32,15). Pranlukast’s mode of 
action is shown in fig. 4. Study done by Morita determined pranlukast was only associated with 
reduced asthma exacerbations in one to five-year-olds. Older age groups experienced no 
Table 1. Lists Montelukast, Pranlukast, Zafirlukast, and Zileuton; commonly used Leukotriene modifiers in the 
treatment of asthma (15).  
significant reduction in exacerbations during the trial (32). The differences in age groups is 
difficult to explain yet may have to do with the number of viral infections occurring in the 
younger age groups (32).   
Zafirlukast has been a heavily studied drug in its effects as an asthma preventer. 
Zafirlukast has been shown to greatly improve asthma symptoms with regards to fewer nighttime 
interruptions, reduced daytime symptoms, and less albuterol use in adults. Children also 
experience a benefit of Zafirlukast use, with improvements at lower ranged dosages. These 
benefits included larger expiratory flow rates in the morning (28%) and evening (41%), fewer 
rescue medications, fewer night awakenings, and 28% reduced B2 agonist use. Quality of life 
was determined to be improved by 18% (15).  
Zileuton inhibits 5-lipooxygenase, it is then thought that the complex forms with the 
enzymes iron molecule in the active site. This follows the inhibition of the neutrophil production 
of LTA4, LTB4, and LTC4 with an efficiency of 80% (14). This allows long term control of 
asthma and may prevent exacerbation with the help of prednisone treatment. Zilueton is also the 
only known drug that can confirmed efficacy in preventing airway obstruction induced by aspirin 
allergens and NSAIDS.  
Analysis has shown that CysLT receptor antagonist are generally less effective than 
inhaled glucocorticoids, but there remains a large gap between effectiveness amongst individual 
patients with asthma. There is no known regimen that will determine which individual will 
respond better to which treatment. Additional treatment with glucocorticoids and CysLt receptor 
antagonists shown an improved asthma control with a lowered dosage use of glucocorticoids 
(12). 
Normally, LTRA’s are taken without much difficulty, however, some adverse effects 
may occur. These affects normally range from headache, abdomen pain, rashes, nausea, 
arthralgia, tremors, depression, and suicidal thinking. However, LTRA’s improved pulmonary 
function and increased baseline forced expiratory volume, as well as increased peak expiratory 
flow. This questionnaire held at the end up the trial concluded that individuals experienced an 
increased quality of life with reduced asthma exacerbations. This has led to the favorability of 
LTRA as an alternative first-line treatment for mild asthma in children (12).  
  
Bronchodilators:  
 
            Bronchodilators, a commonly used treatment for asthma, act as predictors of future lung 
function. Poor bronchodilator response (BDR) has been researched to show poor asthma control 
and is used to identify individuals at risk of poor asthma outcomes (17). Bronchodilators work as 
beta2-agonists, or adrenergic agonists, that relax the smooth muscle of the airway, helps to 
increase muco-ciliary clearance, reduce mediator releasing from mast cells and basophils, and 
can decrease the permeability of the lung’s vasculature (21).  
beta2-agonists therapy can be utilized via aerosol or inhaled methods and has been comparable to 
oral methods. These methods have also shown to have reduced side effects compared to oral 
medications. Most beta2-agosnists have limited durations, normally four to six hours and 
considered short acting, some lasting more than twelve hours and classified as longer acting. 
Longer acting beta2-agosnists are used for allergen-induced asthmatic response or histamine-
induced responses (21). Whereas shorter acting beta2-agonists are the leading therapy choice for 
acute exacerbations and exercise induced asthma. Short acting beta2-agosnists are often used as a 
regularly scheduled control over asthma, yet as been proven to decrease the control of asthma 
and should be kept to a minimum.  
             Beta-adrenoreceptors exist in activated or inactivated forms, activation requires the 
association of the alpha subunit of a G-protein and guanosine triphosphate (GTP). Cyclic 
adenosine monophosphate (cAMP) is produced from ATP, reduces the affinity of the alpha 
subunit to the receptor, and induces smooth muscle cell relaxation. The mechanism of smooth 
muscle cell relation from cAMP is not completely understood yet is thought to result from the 
activation of protein kinase A and phosphorylation of proteins involved in muscle tone control. 
Little evidence has shown cAMP to inhibit the cells intracellular stores of calcium and 
preventing the airway smooth muscle from relaxing (22). Beta2-antagonits bind with high 
affinity for the inactivated form of beta-adrenoreceptor and moves the equilibrium away from the 
activated form (22).     
           Salbutamol, also known as albuterol, is a very common bronchodilator. Salbutamol works 
by selecting binding to and activating beta2 adrenergic receptors and the surface of cells. This 
elicits an inflammatory response primarily seen on CD4 cells, but also on leukocytes with beta2 
receptors, such as macrophages, monocytes, Langerhans cells. Binding of beta2 receptor agonist 
inhibits inflammatory gene expression of IL2 and interferon gamma (23). Salbutamol increases 
PEF up to 90% after inhalation yet returns to nearly baseline after only six hours. Indicating it 
has a very short duration as expected with beta2 antagonists (24).  
         Salmeterol, also known as Serevent, is used a longer acting bronchodilator as compared to 
salbutamol (24).  Salmeterol’s smooth muscle relaxation of the airway is accompanied by a slow 
onset yet long duration. The long duration is attributed to Salmeterol binding to the Beta2-
adrenoreceptors active site, as well as binding to a saligenin moiety of a different site (30). 
Salmeterol has been proven to increase peak expiratory flow, as well as increased FEV and 
airway responsiveness when compared to that of placebos in study (25). Salmeterol has a more 
prolonged peak flow when compared to salbutamol by several hours, making it a longer acting 
medication (24).  
Anticholinergics, such as ipratropium bromide, act by reducing intrinsic vagal tone in the lung’s 
airways upon inhalation working to block post-ganglionic efferent pathways. Their effects in 
controlling asthma symptoms are similar to that of beta2-agonists and are normally prescribed 
together (31). Anticholinergics 
target M1, M2, and M3 
muscarinic receptors 
responsible for binding 
acetylcholine (38). 
Acetylcholine is the primary 
neurotransmitter in the airway, 
binding to the epithelial cells, 
smooth muscle cells and 
submucosal glands within the 
airway. As seen in fig. 5, 
binding of the muscarinic receptors leads to a downstream effect of airway symptoms such as: 
Broncho restriction, airway hyperreactivity, smooth muscle thickening, and extracellular matrix 
deposition (35). The combination of anticholinergics and beta2-agosnists has been established to 
have greater bronchodilation than each agent alone (31). Anticholinergics often have a delayed 
Figure 5. Summary of acetylcholine’s effect in the pathophysiology of 
asthma. Binding of acetylcholine to the muscarinic receptors triggers the 
downstream effects of asthma (35).  
reaction time after administering or overall reduced effect yet can have a more positive effect if 
taken with a beta2-agosnist (21).  
            A longer acting anticholinergic tiotropium bromide has been shown to increase lung 
function, asthma control, and decrease exacerbations. Studies have shown tiotropium bromide to 
be well tolerated and safe. Studies have shown to have increased FEV1 by 102 mL, as well as 
decreasing the number of exacerbations compared to those on placebos (18).  
  
Conclusion:  
 
           In conclusion, there is a wide variety of treatments to control the symptoms of asthma. 
The clinician’s role is vital in ensuring the proper medications are administered to better aid the 
patient in their fight over asthma. This emphasizes the need for continued research into the 
process of development as well as the prevention of asthma and its symptoms. Today’s use of 
monoclonal antibodies, corticosteroids, leukotriene modifiers, and bronchodilators have 
increased the daily living of individuals affected by asthma. Each class of medication has its 
function in controlling different phenotypes of asthma and therefore limits itself to asthmas 
broad spectrum of inflammation. Asthma research has provided victims symptom relief that 
specifically targets their inflammation, allergic or non-allergic. Clinicians are able to determine 
the best treatment plans for individuals centered around their physiologic disruptions attributed 
form asthma. This has enabled individuals to receive treatment that not only works to control 
their symptoms, but also allows them to take their medication at their level of comfort and need.  
Implications:  
          This review exemplifies the diversity of asthma control methods as well as the multitude 
of physiological pathways asthma uses to inflict symptoms onto the human body.  This review 
also illustrates how certain medications are used to control such symptoms. Research into 
asthma’s diverse physiological pathways utilized to induce symptoms demands the development 
of specific medications for better asthma management and control.  
Limitations:  
           Asthma elicits a multitude of effects on the human body, this review was limited to the 
most common methods used to treat asthma. This review is also limited towards the development 
of asthma, as its development can largely be multifactorial. Treating each patient may require 
more than the described medications as mentioned above.  
Future Research:  
          Future asthma research has many avenues to continue its understanding of asthma. 
Different medications that have greater control over asthma as well as reduced side effects would 
make large strides towards improving daily conflicts confronted with its victims. Many 
medications are aimed at the control of symptoms, as well as prevention of exacerbations caused 
by asthma. Research into preventing the overall cause of symptoms while preventing asthma 
symptoms from ultimately occurring is greatly needed. Once these are discovered, the overall 
prevention of asthma can occur.  
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